Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysis Research Letter

  

Authors:	Costa, B. A.; Costa, T. A.; Pak, K.; Patel, A.; Felix, N.; Mouhieddine, T. H.; Richter, J.
Title:	Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysis
Keywords:	treatment outcome; treatment response; lenalidomide; mortality; comparative study; antineoplastic agent; letter; progression free survival; bortezomib; proteasome; proteasome inhibitor; multiple myeloma; antineoplastic combined chemotherapy protocols; dexamethasone; steroid; systematic review; warfarin; drug therapy; oligopeptides; meta analysis; carfilzomib; progression-free survival; eculizumab; oligopeptide; pomalidomide; humans; human; daratumumab; isatuximab
Journal Title:	American Journal of Hematology
Volume:	99
Issue:	7
ISSN:	0361-8609
Publisher:	John Wiley & Sons, Inc.
Date Published:	2024-07-01
Start Page:	1411
End Page:	1414
Language:	English
DOI:	10.1002/ajh.27314
PUBMED:	38606993
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85190523120&doi=10.1002%2fajh.27314&partnerID=40&md5=ac08f674a62e497aedf877d84b511418
Notes:	Letter -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/216968